



Dr. Vinay Chopr MD (Pathology & Micr Chairman & Consultar		obiology)	Dr. Yugam MD (I CEO & Consultant F	Pathology)
NAME	: Mr. MOHIT MEHTA			
AGE/ GENDER	: 42 YRS/MALE	PA	ATIENT ID	: 1675826
COLLECTED BY	:	RE	EG. NO./LAB NO.	: 012411190005
REFERRED BY	:	RE	EGISTRATION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	: 01521057		DLLECTION DATE	: 19/Nov/2024 08:12AM
CLIENT CODE. CLIENT ADDRESS	: KOS DIAGNOSTIC LAB		EPORTING DATE	: 19/Nov/2024 09:04AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMB.	ALA CANT I		
Test Name		Value	Unit	Biological Reference interval
			LNESS PANEL: G D COUNT (CBC)	
RED BLOOD CELLS	(RBCS) COUNT AND INDICES			
HAEMOGLOBIN (HI by CALORIMETRIC	B)	15.6	gm/dL	12.0 - 17.0
RED BLOOD CELL (1		5.55 ^H	Millions/c	mm 3.50 - 5.00
by HYDRO DYNAMIC F	OCUSING, ELECTRICAL IMPEDENCE	48.1	%	40.0 - 54.0
by CALCULATED BY A	UTOMATED HEMATOLOGY ANALYZER			
MEAN CORPUSCULA by CALCULATED BY A	AR VOLUME (MCV) UTOMATED HEMATOLOGY ANALYZER	86.6	fL	80.0 - 100.0
	AR HAEMOGLOBIN (MCH) UTOMATED HEMATOLOGY ANALYZER	28.1	pg	27.0 - 34.0
MEAN CORPUSCUL	AR HEMOGLOBIN CONC. (MCHC) UTOMATED HEMATOLOGY ANALYZER	32.4	g/dL	32.0 - 36.0
RED CELL DISTRIB	UTION WIDTH (RDW-CV)	13	%	11.00 - 16.00
RED CELL DISTRIB	UTOMATED HEMATOLOGY ANALYZER UTION WIDTH (RDW-SD) UTOMATED HEMATOLOGY ANALYZER	42.1	fL	35.0 - 56.0
MENTZERS INDEX		15.6	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING IND by calculated WHITE BLOOD CEI		20.28	RATIO	BETA THALASSEMIA TRAIT:< 65.0 IRON DEFICIENCY ANEMIA: > 65.0
vv m i i r Kitiliii (H		8930	/cmm	4000 - 11000
		0930	/ CIIIIII	4000 - 11000
FOTAL LEUCOCYTE	BY SF CUBE & MICROSCOPY			
FOTAL LEUCOCYTE by flow cytometry NUCLEATED RED B		NIL		0.00 - 20.00





DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com
 www.koshealthcare.com



Page 1 of 14





Dr. Vinay Chopra Dr. Yugam Chopra MD (Pathology & Microbiology) MD (Pathology) Chairman & Consultant Pathologist **CEO & Consultant Pathologist** NAME : Mr. MOHIT MEHTA AGE/ GENDER : 42 YRS/MALE **PATIENT ID** :1675826 **COLLECTED BY** REG. NO./LAB NO. :012411190005 **REFERRED BY REGISTRATION DATE** : 19/Nov/2024 07:58 AM **BARCODE NO.** :01521057 **COLLECTION DATE** : 19/Nov/2024 08:12AM CLIENT CODE. : KOS DIAGNOSTIC LAB **REPORTING DATE** : 19/Nov/2024 09:04AM **CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT Test Name Value Unit **Biological Reference interval DIFFERENTIAL LEUCOCYTE COUNT (DLC) NEUTROPHILS** 62 % 50 - 70 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY LYMPHOCYTES 28 % 20 - 40 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY EOSINOPHILS 3 % 1 - 6 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY MONOCYTES 7 % 2 - 12by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY BASOPHILS 0 % 0 - 1 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY **ABSOLUTE LEUKOCYTES (WBC) COUNT** ABSOLUTE NEUTROPHIL COUNT 5537 2000 - 7500 /cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE LYMPHOCYTE COUNT 2500 800 - 4900 /cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE EOSINOPHIL COUNT 268/cmm 40 - 440 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE MONOCYTE COUNT 625 /cmm 80 - 880 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE BASOPHIL COUNT 0 /cmm 0 - 110 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY PLATELETS AND OTHER PLATELET PREDICTIVE MARKERS.

PLATELET COUNT (PLT) 380000 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE 0.41^H PLATELETCRIT (PCT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE MEAN PLATELET VOLUME (MPV) 11 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELET LARGE CELL COUNT (P-LCC) 122000^H by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELET LARGE CELL RATIO (P-LCR) 32.2 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELET DISTRIBUTION WIDTH (PDW) 16.4by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

/cmm

/cmm

%

fL

%

%



150000 - 450000

0.10 - 0.36

6.50 - 12.0

11.0 - 45.0

15.0 - 17.0

30000 - 90000

Page 2 of 14





	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Patholog		(Pathology)
NAME	: Mr. MOHIT MEHTA		
AGE/ GENDER	: 42 YRS/MALE	PATIENT ID	: 1675826
COLLECTED BY	:	REG. NO./LAB NO.	: 012411190005
REFERRED BY	:	REGISTRATION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	: 01521057	COLLECTION DATE	: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 19/Nov/2024 09:04AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANT	Т	
Test Name	Value	Unit	Biological Reference interval



V DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







Dr. Vinay ChopraDr. Yugam ChopraMD (Pathology & Microbiology)MD (Pathology)Chairman & Consultant PathologistCEO & Consultant Pathologist				
NAME	: Mr. MOHIT MEHTA			
AGE/ GENDER	: 42 YRS/MALE	PATI	ENT ID	: 1675826
COLLECTED BY	:	REG. 1	NO./LAB NO.	: 012411190005
REFERRED BY		REGIS	TRATION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	: 01521057			: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB			: 19/Nov/2024 03:25PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,			. 10/ NOV/ 202 1 00.201 M
Test Name		Value	Unit	Biological Reference interval
GLYCOSYLATED HAEM WHOLE BLOOD		COSYLATED HAEMO 10.1 ^H	GLOBIN (HBA1C) %	4.0 - 6.4
ESTIMATED AVERAGE	NCE LIQUID CHROMATOGRAPHY) PLASMA GLUCOSE NCE LIQUID CHROMATOGRAPHY)	243.17 ^H	mg/dL	60.00 - 140.00
ADVICE INTERPRETATION:		KINDLY CORREL	ATE CLINICALLY	
	AS PER AMERICAN DIA	BETES ASSOCIATION (ADA):		
REF	ERENCE GROUP		EMOGLOGIB (HBAIC) in %	
	tic Adults >= 18 years		<5.7	
	sk (Prediabetes)		5.7 - 6.4	
Diagr	nosing Diabetes		>= 6.5	
			e > 19 Years	
Therapoutic a	oals for glycemic control	Goals of Therapy:	< 7.0	
merapeutic y		Actions Suggested:	>8.0	
		Goal of therapy:	e < 19 Years <7.5	

TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropiate. 4.High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







Test Name		Value Unit	Biological Reference interva
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT	
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 19/Nov/2024 03:25PM
BARCODE NO.	:01521057	COLLECTION DATE	: 19/Nov/2024 08:12AM
REFERRED BY	:	REGISTRATION DATE	E : 19/Nov/2024 07:58 AM
COLLECTED BY	:	REG. NO./LAB NO.	: 012411190005
AGE/ GENDER	: 42 YRS/MALE	PATIENT ID	: 1675826
NAME	: Mr. MOHIT MEHTA		
	MD (Pathology & Chairman & Cons	C, /	1D (Pathology) ant Pathologist
	Dr. Vinay Cho	opra 🕴 Dr. Yuga	am Chopra







DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Cho MD (Pathology & N Chairman & Consu	licrobiology)	Dr. Yugam MD (I CEO & Consultant F	Pathology)
AME	: Mr. MOHIT MEHTA			
GE/ GENDER	: 42 YRS/MALE	PAT	ENT ID	: 1675826
DLLECTED BY	:	REG.	NO./LAB NO.	: 012411190005
EFERRED BY	:	REG	STRATION DATE	: 19/Nov/2024 07:58 AM
ARCODE NO.	: 01521057	COLL	ECTION DATE	: 19/Nov/2024 08:12AM
LIENT CODE.	: KOS DIAGNOSTIC LAB	REP	DRTING DATE	: 19/Nov/2024 09:22AM
IENT ADDRESS	: 6349/1, NICHOLSON ROAD, AN	MBALA CANTT		
est Name		Value	Unit	Biological Reference interval
An ESR can be affe C-reactive protein This test may also stemic lupus erythe DNDITION WITH LO Iow ESR can be see olycythaemia), sigr sickle cells in sickl DTE: ESR and C - reactiv Generally, ESR doe CRP is not affected If the ESR is elevat Women tend to ha Drugs such as dext	be used to monitor disease activity ematosus W ESR n with conditions that inhibit the n ificantly high white blood cell cou e cell anaemia) also lower the ESR e protein (C-RP) are both markers of rs not change as rapidly as does CR by as many other factors as is ESR, ed, it is typically a result of two typ ve a higher ESR, and menstruation	flammation. For this and response to the ormal sedimentation (leucocytosis), an chinflammation. P, either at the start making it a better m and pregnancy can c	reason, the ESR is typi erapy in both of the ab n of red blood cells, sur d some protein abnorn of inflammation or as arker of inflammation. lins or fibrinogen. ause temporary elevat	icallý used in conjunction with other test such ove diseases as well as some others, such as ch as a high red blood cell count malities. Some changes in red cell shape (such it resolves.





DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com



Page 6 of 14





	MD	: Vinay Chopra) (Pathology & Micr airman & Consultan	obiology)	Dr. Yugan MD CEO & Consultant	(Pathology)
NAME	: Mr. MOHIT ME	НТА			
AGE/ GENDER	: 42 YRS/MALE		PATI	IENT ID	: 1675826
COLLECTED BY	:		REG.	NO./LAB NO.	: 012411190005
REFERRED BY	:		REGI	STRATION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	:01521057		COLL	LECTION DATE	: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOST	IC LAB	REPO	ORTING DATE	: 19/Nov/2024 12:56PM
CLIENT ADDRESS	: 6349/1, NICHO	LSON ROAD, AMBA	ALA CANTT		
Test Name			Value	Unit	Biological Reference interval
		CLINICAL	CHEMISTRY	/BIOCHEMIST	'RY
		(LUCOSE FAS	TING (F)	
GLUCOSE FASTING	G (F): PLASMA	D-POD)	228.52 ^H	mg/dL	NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0

IN ACCRDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES: 1. A fasting plasma glucose level below 100 mg/dl is considered normal. 2. A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood

test (after consumption of 75 gms of glucose) is recommended for all such patients. 3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



Page 7 of 14



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



		hopra & Microbiology) nsultant Pathologist CEC		n Chopra (Pathology) Pathologist
NAME	: Mr. MOHIT MEHTA			
AGE/ GENDER	: 42 YRS/MALE	PATIENT I	D	: 1675826
COLLECTED BY	:	REG. NO./I	AB NO.	: 012411190005
REFERRED BY	:	REGISTRA	FION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	:01521057	COLLECTIO	ON DATE	: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTIN	G DATE	: 19/Nov/2024 10:45AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD	, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
		LIPID PROFILE : BA	SIC	
CHOLESTEROL TOT	TAL · SFRUM	240.04 ^H	mg/dL	OPTIMAL: < 200.0
by CHOLESTEROL OX		240.04"	ilig/ uL	BORDERLINE HIGH: 200.0 -
				239.0
				HIGH CHOLESTEROL: > OR = 240.0
FRIGLYCERIDES: S	ERUM	573.45 ^H	mg/dL	OPTIMAL: < 150.0
by GLYCEROL PHOSP	PHATE OXIDASE (ENZYMATIC)			BORDERLINE HIGH: 150.0 -
				199.0 HIGH: 200.0 - 499.0
				VERY HIGH: $> OR = 500.0$
	L (DIRECT): SERUM	38.68	mg/dL	LOW HDL: < 30.0
by SELECTIVE INHIBITI	ION			BORDERLINE HIGH HDL: 30.0 60.0
				HIGH HDL: $> OR = 60.0$
LDL CHOLESTEROI		NOT CALCULATED	mg/dL	OPTIMAL: < 100.0
by CALCULATED, SPE	CIROPHOTOMETRY			ABOVE OPTIMAL: 100.0 - 129. BORDERLINE HIGH: 130.0 -
				159.0
				HIGH: 160.0 - 189.0
NON HDL CHOLEST	TEROI · SERUM	901 20H	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0
by CALCULATED, SPE		201.36 ^H	ilig/ uL	ABOVE OPTIMAL: 130.0 - 159.
				BORDERLINE HIGH: 160.0 -
				189.0 HIGH: 190.0 - 219.0
				VERY HIGH: $> OR = 220.0$
VLDL CHOLESTERO		NOT CALCULATED	mg/dL	0.00 - 45.00
by CALCULATED, SPE		NOT CALCULATED	mg/dL	350.00 - 700.00
by CALCULATED, SPE	CTROPHOTOMETRY		-	
CHOLESTEROL/HD by CALCULATED, SPE		6.21 ^H	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0
.,,,, or L				MODERATE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0
				HIGH RISK: > 11.0
15.133.20	2	Λ		



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

yhoira

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



Page 8 of 14





		& Microbiology)	Dr. Yugam MD & Consultant	(Pathology)
NAME	: Mr. MOHIT MEHTA			
AGE/ GENDER	: 42 YRS/MALE	PATIENT ID)	: 1675826
COLLECTED BY	:	REG. NO./L/	AB NO.	: 012411190005
REFERRED BY	:	REGISTRAT	ION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	: 01521057	COLLECTIO	N DATE	: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING	G DATE	: 19/Nov/2024 10:45AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD	, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
LDL/HDL RATIO: S by CALCULATED, SPE		NOT CALCULATED	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/H by CALCULATED, SPE	IDL RATIO: SERUM	14.83 ^H	RATIO	3.00 - 5.00
NOTE 2		WHEN TRIGLYCERID LDL AND VLDL ARE N		400 mg/dL THE CALCULATED VALUES O LE
ADVICE		KINDLY CORRELATE	E CLINICALL	Y

INTERPRETATION:

1.Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogenic) ported by the text as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Chop MD (Pathology & Mic Chairman & Consulta	crobiology)		(Pathology)
NAME	: Mr. MOHIT MEHTA			
AGE/ GENDER	: 42 YRS/MALE		PATIENT ID	: 1675826
COLLECTED BY	:		REG. NO./LAB NO.	: 012411190005
REFERRED BY	:		REGISTRATION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	:01521057		COLLECTION DATE	: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 19/Nov/2024 10:45AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMI	BALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	LIVER	FUNCTIO	N TEST (COMPLETE)	
BILIRUBIN TOTAL	: SERUM PECTROPHOTOMETRY	0.61	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
	Г (CONJUGATED): SERUM spectrophotometry	0.12	mg/dL	0.00 - 0.40
	ECT (UNCONJUGATED): SERUM	0.49	mg/dL	0.10 - 1.00
SGOT/AST: SERUN by IFCC, WITHOUT PY	[/RIDOXAL PHOSPHATE	23.8	U/L	7.00 - 45.00
SGPT/ALT: SERUM	[/RIDOXAL PHOSPHATE	30.9	U/L	0.00 - 49.00
AST/ALT RATIO: S by CALCULATED, SPI	ERUM ECTROPHOTOMETRY	0.77	RATIO	0.00 - 46.00
ALKALINE PHOSP by PARA NITROPHEN PROPANOL	HATASE: SERUM IYL PHOSPHATASE BY AMINO METHYL	115.1	U/L	40.0 - 130.0
GAMMA GLUTAMY by SZASZ, SPECTRO	L TRANSFERASE (GGT): SERUM	82.26 ^H	U/L	0.00 - 55.0
TOTAL PROTEINS: by BIURET, SPECTRO		7.62	gm/dL	6.20 - 8.00
ALBUMIN: SERUM		4.37	gm/dL	3.50 - 5.50
GLOBULIN: SERUM		3.25	gm/dL	2.30 - 3.50
A : G RATIO: SERU		1.34	RATIO	1.00 - 2.00

by CALCULATED, SPECTROPHOTOMETRY

INTERPRETATION

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range.

USE:- Differential diagnosis of diseases of hepatobiliary system and pancreas.

INCREASED:

DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS	> 1.3 (Slightly Increased)





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	Dr. Vinay Chopra MD (Pathology & Microbiolog Chairman & Consultant Patho		(Pathology)
NAME	: Mr. MOHIT MEHTA		
AGE/ GENDER	: 42 YRS/MALE	PATIENT ID	: 1675826
COLLECTED BY	:	REG. NO./LAB NO.	: 012411190005
REFERRED BY	:	REGISTRATION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	: 01521057	COLLECTION DATE	: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 19/Nov/2024 10:45AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CA	NTT	

DECREASED:

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

PROGNOSTIC SIGNIFICANCE:

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Cho MD (Pathology & M Chairman & Consu	1icrobiology)		(Pathology)				
NAME	: Mr. MOHIT MEHTA							
AGE/ GENDER	: 42 YRS/MALE		PATIENT ID	: 1675826				
COLLECTED BY	:		REG. NO./LAB NO.	: 012411190005				
REFERRED BY	:		REGISTRATION DATE	: 19/Nov/2024 07:58 AM				
BARCODE NO.	: 01521057		COLLECTION DATE	: 19/Nov/2024 08:12AM				
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 19/Nov/2024 10:45AM				
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AN	6349/1, NICHOLSON ROAD, AMBALA CANTT						
Test Name		Value	Unit	Biological Reference interv				
	KIDNE	EY FUNCTIO	ON TEST (COMPLETE)					
UREA: SERUM		18.35	mg/dL	10.00 - 50.00				
-	ATE DEHYDROGENASE (GLDH)	1.05	mg /dI	0.40 1.40				
CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETERY		1.05	mg/dL	0.40 - 1.40				
BLOOD UREA NITROGEN (BUN): SERUM		8.57	mg/dL	7.0 - 25.0				
by CALCULATED, SPECTROPHOTOMETRY BLOOD UREA NITROGEN (BUN)/CREATININE		8.16 ^L	RATIO	10.0 - 20.0				
RATIO: SERUM		0.10						
by CALCULATED, SPECUREA/CREATININE		17.48	RATIO					
by CALCULATED, SPE	CTROPHOTOMETRY							
URIC ACID: SERUM by URICASE - OXIDASE		7.42	mg/dL	3.60 - 7.70				
CALCIUM: SERUM		10.36	mg/dL	8.50 - 10.60				
by ARSENAZO III, SPEC PHOSPHOROUS: SE		3.77	ma /dI	2.30 - 4.70				
	ATE, SPECTROPHOTOMETRY	3.11	mg/dL	2.30 - 4.70				
<u>ELECTROLYTES</u>								
SODIUM: SERUM		144.3	mmol/L	135.0 - 150.0				
by ISE (ION SELECTIVE ELECTRODE) POTASSIUM: SERUM		4.05	mmol/L	3.50 - 5.00				
by ISE (ION SELECTIVE ELECTRODE)								
CHLORIDE: SERUM by ISE (ION SELECTIVE		108.23	mmol/L	90.0 - 110.0				
	ERULAR FILTERATION RATE							
ESTIMATED GLOMI (eGFR): SERUM by CALCULATED	ERULAR FILTERATION RATE	90.9						
INTERPRETATION:	een nre- and nost renal azotemia							

To differentiate between pre- and post renal azotemia.

INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.

2. Catabolic states with increased tissue breakdown.

3. GI haemorrhage.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist		Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist					
NAME	: Mr. MOHIT M	ЕНТА						
AGE/ GENDER	: 42 YRS/MALE		P	ATIENT ID	:1	675826		
COLLECTED BY	:		R	EG. NO./LAB NO	. :0	1241119000	05	
REFERRED BY	:		R	EGISTRATION D	ATE : 1	9/Nov/2024 0)7:58 AM	
BARCODE NO.	:01521057			DLLECTION DAT		9/Nov/2024 0		
CLIENT CODE.	: KOS DIAGNOS	TIC LAB		EPORTING DAT		9/Nov/2024 1		
CLIENT ADDRESS		OLSON ROAD, AMBA						
Test Name			Value	Un	uit	Biologi	ical Referer	nce interva
INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia	tetracycline, gluc 0:1) WITH ELEVAT (BUN rises disprosed on	ED CREATININE LEVE oportionately more t renal disease.	LS:) (e.g. obstructive	e uropathy).			
INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (< 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome of 8. Pregnancy. DECREASED RATIO (< 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERL CKD STAGE G1	tetracycline, gluci 0:1) WITH ELEVAT (BUN rises dispro- superimposed on 0:1) WITH DECRE/ osis. Ind starvation. creased urea synt urea rather than monemias (urea i if inappropiate an 0:1) WITH INCREA py (accelerates co- eleases muscle cr who develop rena : sis (acetoacetate creased BUN/crea apy (interferes wi ULAR FILTERATION Norm	ocorticoids) ED CREATININE LEVE oportionately more t renal disease. ASED BUN : ASED BUN : ASED BUN : ASED CREATININE: onversion of creatine eatinine). al failure. causes false increase atinine ratio). th creatinine measur RATE: DESCRIPTION al kidney function	LS: han creatinine ut of extracell blood). due to tubular to creatinine; e in creatinine rement).	ular fluid). secretion of urea with certain met <u>'min/1.73m2)</u> >90	a. thodologies,r ASSOCIA No p	TED FINDINGS		hen dehydra
NCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (< 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome of 8. Pregnancy. DECREASED RATIO (< 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients NAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERL OKD STAGE	tetracycline, gluci 0:1) WITH ELEVAT (BUN rises dispro- superimposed on 0:1) WITH DECRE/ osis. ad starvation. creased urea synt urea rather than monemias (urea i of inappropiate an 0:1) WITH INCREA py (accelerates co- eleases muscle cr who develop rena : sis (acetoacetate creased BUN/crea apy (interferes wi JLAR FILTERATION Norm	ocorticoids) ED CREATININE LEVE oportionately more t renal disease. ASED BUN : ASED BUN : ASED BUN : ASED CREATININE: onversion of creatine eatinine). al failure. causes false increase atinine ratio). th creatinine measur RATE: DESCRIPTION al kidney function ney damage with	LS: han creatinine ut of extracell blood). due to tubular to creatinine; e in creatinine rement).	ular fluid). secretion of urea with certain met /min/1.73m2)	a. thodologies,r ASSOCIA No p Presence	TED FINDINGS roteinuria e of Protein ,		hen dehydra
INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (< 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome of 8. Pregnancy. DECREASED RATIO (< 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERI CKD STAGE G1 G2	tetracycline, gluci 0:1) WITH ELEVAT (BUN rises dispro- superimposed on 0:1) WITH DECRE/ osis. ad starvation. creased urea synt urea rather than monemias (urea i of inappropiate an 0:1) WITH INCREA py (accelerates co- eleases muscle cr who develop rena : sis (acetoacetate creased BUN/crea apy (interferes wi JLAR FILTERATION Norm Kidin nor	ocorticoids) ED CREATININE LEVE oportionately more t renal disease. ASED BUN : ASED BUN : ASED BUN : ASED CREATININE: onversion of creatine eatinine). al failure. causes false increase atinine ratio). th creatinine measur RATE: DESCRIPTION al kidney function mey damage with mal or high GFR	LS: han creatinine ut of extracell blood). due to tubular to creatinine; e in creatinine rement).	ular fluid). secretion of urea with certain met <u>/min/1.73m2)</u> >90 >90	a. thodologies,r ASSOCIA No p Presence	TED FINDINGS		hen dehydra
INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (< 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome of 8. Pregnancy. DECREASED RATIO (< 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERL CKD STAGE G1	tetracycline, gluci 0:1) WITH ELEVAT (BUN rises dispro- superimposed on 0:1) WITH DECRE/ osis. Ind starvation. Creased urea synt urea rather than monemias (urea i of inappropiate an 0:1) WITH INCRE/ py (accelerates co- eleases muscle cr who develop rena : sis (acetoacetate creased BUN/crea apy (interferes wi <u>UAR FILTERATION</u> Norm Kidu nor	ocorticoids) ED CREATININE LEVE oportionately more t renal disease. ASED BUN : ASED BUN : ASED BUN : ASED CREATININE: onversion of creatine eatinine). al failure. causes false increase atinine ratio). th creatinine measur RATE: DESCRIPTION al kidney function ney damage with	LS: han creatinine ut of extracell blood). due to tubular to creatinine) e in creatinine rement).	ular fluid). secretion of urea with certain met <u>'min/1.73m2)</u> >90	a. thodologies,r ASSOCIA No p Presence	TED FINDINGS roteinuria e of Protein ,		hen dehydra
INCREASED RATIO (>2 1. Postrenal azotemia 2. Prerenal azotemia DECREASED RATIO (< 1. Acute tubular necr 2. Low protein diet ar 3. Severe liver disease 4. Other causes of de 5. Repeated dialysis (6. Inherited hyperam 7. SIADH (syndrome of 8. Pregnancy. DECREASED RATIO (< 1. Phenacimide thera 2. Rhabdomyolysis (r 3. Muscular patients INAPPROPIATE RATIO 1. Diabetic ketoacido should produce an in 2. Cephalosporin ther ESTIMATED GLOMERU CKD STAGE G1 G2 G3a	tetracycline, gluci 0:1) WITH ELEVAT (BUN rises dispro- superimposed on 0:1) WITH DECRE/ osis. Ind starvation. Creased urea synt urea rather than monemias (urea i of inappropiate an 0:1) WITH INCRE/ py (accelerates co- eleases muscle cr who develop rena : sis (acetoacetate creased BUN/crea apy (interferes wi <u>UAR FILTERATION</u> Norm Kidu nor Moder Sever	ocorticoids) ED CREATININE LEVE oportionately more t renal disease. ASED BUN : ASED BUN : ASED BUN : ASED CREATININE: onversion of creatine eatinine). al failure. causes false increase atinine ratio). th creatinine measure RATE: DESCRIPTION nal kidney function ney damage with mal or high GFR decrease in GFR	LS: han creatinine ut of extracell blood). due to tubular to creatinine) e in creatinine rement).	ular fluid). secretion of urea with certain met <u>/min/1.73m2)</u> >90 >90	a. thodologies,r ASSOCIA No p Presence	TED FINDINGS roteinuria e of Protein ,		hen dehydra



DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)









	Dr. Vinay Chopra MD (Pathology & Microbiology Chairman & Consultant Pathol		(Pathology)
NAME	: Mr. MOHIT MEHTA		
AGE/ GENDER	: 42 YRS/MALE	PATIENT ID	: 1675826
COLLECTED BY	:	REG. NO./LAB NO.	: 012411190005
REFERRED BY	:	REGISTRATION DATE	: 19/Nov/2024 07:58 AM
BARCODE NO.	: 01521057	COLLECTION DATE	: 19/Nov/2024 08:12AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 19/Nov/2024 10:45AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CAN	NTT	
Test Name	Value	Unit	Biological Reference interval

COMMENTS:

Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney.
 eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012
 In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure of CFD with the commended to measure

3. In patients, with eGFR cleaning between 45-59 minimit 1.73 m2 (G3) and without any marker of Kidney damage, it is recommended to measure eGFR with Cystatin C for confirmation of CKD
4. eGFR category G1 OR G2 does not fulfill the criteria for CKD, in the absence of evidence of Kidney Damage
5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure
6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C
7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated

End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

